The rise of GLP-1s, which were initially approved for diabetes management and later for obesity treatment, underscores this ...

Diabetes affects millions worldwide, often triggering complications such as insulin resistance and fatty liver disease. To ...

TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...

Alongside this research, other studies have shown that lifestyle choices can also help manage diabetes. Eating more whole ...

This simple, cost-effective tool has the potential to revolutionize type 2 diabetes care, helping millions of people ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

For instance, some type 2 diabetes medications can cause hypoglycemia when taken together, so you and your doctor should also consider your current treatment if you’re adding a new medication to ...

Biomedical engineer Joshua Doloff uses federal funding to pioneer immunotherapies that could free diabetes patients from ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Broad access to new obesity drugs leads to longer, healthier lives, delivering a substantial societal return on investment, ...

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...